TBI/fludarabine versus busulfan/fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allo-HCT. A study from the ALWP of the EBMT
| dc.contributor.author | Swoboda, R. | |
| dc.contributor.author | Labopin, M. | |
| dc.contributor.author | Giebel, S. | |
| dc.contributor.author | Schroeder, T. | |
| dc.contributor.author | Kroeger, N. | |
| dc.contributor.author | Arat, M. | |
| dc.contributor.author | Savani, B. | |
| dc.contributor.author | Spyridonidis, A. | |
| dc.contributor.author | Hamladji, R. M. | |
| dc.contributor.author | Potter, V. | |
| dc.contributor.author | Deconinck, E. | |
| dc.contributor.author | Yakoub-Agha, I. | |
| dc.contributor.author | Rambaldi, A. | |
| dc.contributor.author | Ozdogu, H. | |
| dc.contributor.author | Sanz, J. | |
| dc.contributor.author | Nagler, A. | |
| dc.contributor.author | Mohty, M. | |
| dc.date.accessioned | 2023-01-04T11:29:37Z | |
| dc.date.available | 2023-01-04T11:29:37Z | |
| dc.date.issued | 2022 | |
| dc.identifier.endpage | 35 | en_US |
| dc.identifier.issn | 0268-3369 | en_US |
| dc.identifier.issue | Supplement 1 | en_US |
| dc.identifier.startpage | 35 | en_US |
| dc.identifier.uri | http://hdl.handle.net/11727/8549 | |
| dc.identifier.volume | 57 | en_US |
| dc.identifier.wos | 000878153300055 | en_US |
| dc.language.iso | eng | en_US |
| dc.relation.journal | BONE MARROW TRANSPLANTATION | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.title | TBI/fludarabine versus busulfan/fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allo-HCT. A study from the ALWP of the EBMT | en_US |
| dc.type | conferenceObject | en_US |